Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Issue 9 (28th July 2020)

• Record Type: Journal Article
• Authors: Coyle, Luke; Morley, Nicholas J.; Rambaldi, Alessandro; Mason, Kylie D.; Verhoef, Gregor; Furness, Caroline L.; Zhang, Alicia; Jung, A. Scott; Cohan, David; Franklin, Janet L.
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 9(2020)
• Page Start: 2103
• Page End: 2112
• Publication Date: 2020-07-28
• Subjects: B-cell non-Hodgkin lymphoma -- B-NHL -- salvage therapy -- blinatumomab -- phase 2 trial -- DLBCL; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1759055
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The phase 2 portion of this open-label phase 2/3 study assessed the efficacy and safety of blinatumomab as second salvage for aggressive relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) following platinum-based first salvage chemotherapy. Forty-one patients with aggressive disease (32% relapsed; 68% refractory) enrolled and received stepwise blinatumomab (9–28–112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2; 19 (46%) completed cycle 1 and 3 (7%) completed cycle 2. The overall response rate after 12 weeks was 37%, including 9 (22%) complete metabolic responses. Eight (20%) patients (all responders) subsequently received stem cell transplants. Grade ≥3 adverse events were reported in 29 (71%) patients. Grade 3 cytokine release syndrome occurred in one patient. Grade 3 neurologic events occurred in 10 (24%) patients; all resolved. Blinatumomab monotherapy appears effective as second salvage therapy in patients with r/r aggressive B-NHL. Trial registration: NCT02910063.